Agreement - March 21, 2022
Oasmia signs manufacturing agreement with Lonza
The companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for Oasmia’s investigational drug candidate, Cantrixil. “We are excited to have partnered with Lonza, a global leader in drug manufacturing. The manufacture of Cantrixil is planned to be performed in three steps and this agreement is […]
Biotech Business - January 19, 2022
Oasmia changes name and resolves a new issue of shares
The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights Issue is to finance the continued development of the company and its projects in accordance with its business plan and strategy, it states. Shareholders in […]
Clinical Trials - June 11, 2021
First patient enrolled in Oasmia trial
Oasmia Pharmaceutical has announced that the first patient has been dosed in a Phase 1b clinical trial of its Docetaxel micellar in patients with advanced prostate cancer. The trial is being conducted by the Swiss Group for Clinical Cancer Research (SAKK). “We are pleased to be partnering with SAKK on this trial which we believe […]
Collaboration - March 5, 2021
Oasmia enters collaboration with Karolinska Institutet
The collaboration will generate new information aiming at the development of new therapeutic APIs. The XR-17 platform technology enhances intravenous delivery of established and novel drugs in diseases including cancer, according to Oasmia. The collaboration will include a review of data and experimental methods to gain a deeper understanding of XR-17 and API formulations in […]
Acquisition - March 1, 2021
Oasmia acquires rights for Cantrixil
Oasmia Pharmaceutical has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the first in a series of planned in-licensing deals and acquisitions to expand Oasmia’s oncology portfolio, leveraging its […]
Agreement - October 6, 2020
Oasmia’s partner Elevar Therapeutics signs agreement with Taiba
Oasmia Pharmaceutical announces that Elevar Therapeutics and Taiba Middle East FZ LLC have entered into an exclusive agreement under which Taiba will commercialize and distribute Apealea (micellar paclitaxel) in certain countries throughout the Middle East and North African (MENA) region. Under the terms of the agreement, Taiba will also be responsible for managing named-patient requests […]
